AbbVie Inc. (ABBV) stock news
The latest AbbVie Inc. news and press releases. 0 news stories in the last 24 hours, 0 times its usual daily coverage. ABBV stock report · Market news
Latest news
- Worried investors are paying up for these stocks — some with up to 49% upside, analysts say Market Watch, Nov 18, 4:04 PM UTC
Defensive sectors have beaten the S&P 500 by a wide margin in recent months, even though they are priced much higher relative to earnings estimates than the index. - Invest $100,000 in These 4 Dividend Stocks and Collect Passive Income for Life 24/7 Wall Street, Nov 18, 2:32 PM UTC
Four blue-chip dividend payers, including one that sends checks monthly, offer a way to keep the shares and still get paid. - How Did AbbVie's Neuroscience Franchise Perform in Q3? Zacks Investment Research, Nov 17, 7:06 PM UTC
ABBV's neuroscience franchise delivers 19.5% operational sales growth in Q3, prompting the company to raise its 2026 segment sales outlook to $13 billion. - Invest $200,000 in These 5 Dividend Stocks to Fund Your Retirement Income 247 Wallst, Nov 17, 4:30 PM UTC
Selling shares in a down market can turn a retirement plan into a slow leak. Five dividend payers across five sectors aim to cover the bills instead, but one of them carries $166.2B of debt, and each one hides a risk ... - Forget SCHD: 4 Dividend Stocks Retirees Should Own Instead 24/7 Wall Street, Nov 17, 2:15 PM UTC
The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) grounds countless retirement portfolios. SCHD screens for durable dividend payers, holds $112.3 billion in net assets and pays a trailing yield near 2.94%. - These 3 Dividend Stocks Have Crushed the Market This Year. Here’s Why They Are Still Buys Fool - Investing News, Nov 16, 11:40 PM UTC
They have excellent long-term prospects. - How Retirees Can Turn $175,000 Into Passive Income With These 4 Dividend Stocks 247 Wallst, Nov 15, 12:30 PM UTC
Selling shares to cover bills means accepting whatever price the market offers that month. Four dividend payers from four sectors could replace that gamble, but one of them has already slashed its payout once, and eac... - Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy? The Motley Fool, Nov 14, 9:44 AM UTC
Pfizer offers one of the highest yields in healthcare. AbbVie is a Dividend King with solid growth prospects. - 4 Healthcare Dividend Stocks for Retirees. One Yields Over 4% 247 Wallst, Nov 13, 8:47 PM UTC
A fat starting yield can hide thin raises, while the slowest payers boast decades of increases. Four low-volatility healthcare blue chips force retirees to choose between income today and income that grows, and the ga... - 5 High-Yield Dividend Stocks That Could Beat a 5% Treasury Yield 247 Wallst, Nov 13, 3:47 PM UTC
Treasuries now pay 5.1% with zero equity risk, so dividend stocks have to earn their place in an income portfolio. Five payers pass a stricter test than yield alone, and one of them yields barely half the Treasury rate. - 3 Dividend Stocks Built for a Market Priced Like It's 1999 Fool - Investing News, Nov 13, 9:44 AM UTC
With stocks arguably priced like it's 1999, these three dividend payers could help you weather what comes next. - How Did AbbVie's Immunology Franchise Fare in Q3? Zacks Investment Research, Nov 12, 7:01 PM UTC
ABBV's immunology sales rose 16.6% in Q3, driven by Skyrizi and Rinvoq growth, prompting higher 2026 sales forecasts despite Humira's decline. - 3 Pharmaceutical Stocks That Offer Safety and Growth MarketBeat, Nov 12, 5:12 PM UTC
Market volatility is unpleasant, but it's important that investors don't force themselves into a false choice between safety and growth. Over the last two years, technology stocks, particularly AI stocks, have driven ... - Want a Dividend Check Every Month? This Dividend ETF Paid You 12 Times in the Past Year 247 Wallst, Nov 11, 9:03 PM UTC
A deposit lands every month, but the amounts swing by nearly four times from the smallest check to the largest. Before you build a retirement budget around this fund, see what drives the swings and who should skip it. - ABBV Stock Rises More Than 4% in a Month: Time to Buy, Hold or Sell? Zacks Investment Research, Nov 11, 5:41 PM UTC
AbbVie's strong immunology and neuroscience growth offset Humira erosion and persistent aesthetics and oncology challenges. - 3 Legacy Health Care Dividend Stocks That Never Go Out of Style 247 Wallst, Nov 11, 3:17 PM UTC
Three health care giants have raised dividends for decades, yet each hides a catch that could shrink or stall a retiree's income. One faces lawsuits, one plans a spinoff, and one raises its payout by a single cent. - Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications GuruFocus, Nov 8, 6:00 PM UTC
Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 MedicationsPR Newswir - How Much Do You Need in a Roth IRA at 58 to Replace a $120,000 Salary Tax-Free? 247 Wallst, Nov 7, 7:46 PM UTC
Quitting at 58 sounds simple when your savings sit in a Roth. But one hidden clock, and the wrong conversion pulled at the wrong time, can turn tax-free money into a penalty bill. Find out which dates to check before ... - $600,000 in Dividend Stocks: How a Roth IRA Could Save You $4,460 a Year 247 Wallst, Nov 6, 5:47 PM UTC
Six household-name dividend payers hand you a steady paycheck, but one of them gets taxed far harder than the other five. Find out which holding belongs in a Roth first, and how the bill snowballs over two decades. - 2 Defensive Healthcare Stocks Hitting New 52-Week Highs: ABBV & LLY Zacks Investment Research, Nov 6, 12:26 AM UTC
As tech stocks retreat, AbbVie (ABBV) and Eli Lilly (LLY) are hitting fresh 52-week highs, offering investors defensive healthcare exposure with compelling growth potential. - 5 High-Yield Dividend Stocks Paying Up to 6% With Payouts Built to Last 24/7 Wall Street, Nov 5, 4:17 PM UTC
A fat yield means nothing if the check bounces. Five payers across telecom, tobacco, pharma, real estate and pipelines show how to test coverage, and one of them carries a debt pile that could threaten its raise streak. - Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? Zacks Investment Research, Nov 4, 3:01 PM UTC
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. - Exxon Mobil Just Raised Its Dividend for the 44th Year. Here Are 3 More Wall Street Favorites 24/7 Wall Street, Nov 4, 1:37 PM UTC
Four dividend stocks just delivered strong earnings, but free cash flow and balance sheet strength separate the ones built to keep raising payouts from the ones that just look good on paper. - Dividend Announcements: October 24-30, 2026 (Part 1 Of 2) Seeking Alpha, Nov 4, 1:03 AM UTC
I monitor dividend increases and cuts across 1,200+ stocks, focusing on dividend growth streaks, safety, and valuation to identify conviction opportunities. V, APH, and HIG stand out for robust dividend hikes, high-qu... - AbbVie expands Oxford R&D facility as part of £120 million-plus investment Reuters, Nov 4, 12:08 AM UTC
AbbVie expands Oxford R&D facility as part of £120 million-plus investment - AbbVie Hit a New High After Earnings. There's More Upside Left. 24/7 Wall Street, Nov 3, 4:03 PM UTC
AbbVie just logged a 33% gain for the year and raised its guidance again, but the real question is whether Skyrizi and a newly closed pipeline deal can push shares even further past a valuation that already looks stre... - AbbVie Inc. $ABBV Position Lessened by BOCHK Asset Management Ltd Defense World, Nov 3, 8:47 AM UTC
BOCHK Asset Management Ltd cut its holdings in AbbVie Inc. (NYSE: ABBV) by 52.4% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The in... - AbbVie's Humira Era Is Fading, But Its New Growth Engines Face Another Test MarketBeat, Nov 2, 6:16 PM UTC
AbbVie TodayABBVAbbVie$288.82 -6.07 (-2.06%) As of 01:16 PM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$190.75▼$298.74Dividend Yield2.40%P/E Ratio49.69Price Target$285.89Add... - The Best Dividend Stocks to Buy With $5,000 in November The Motley Fool, Nov 2, 5:15 PM UTC
AbbVie survived its loss of Humira, and its profits are soaring. J&J's streamlining efforts are paying off. - ABBV Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress Zacks Investment Research, Nov 2, 4:01 PM UTC
AbbVie raises its 2026 revenue and earnings outlook as Skyrizi, Rinvoq and neuroscience growth fuel momentum, while oncology milestones shape prospects.
Press releases
- Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications PRNewsWire, Nov 8, 5:45 PM UTC
– HARMONY IN DIVERSITY is the first study of combined neurotoxin and filler treatment in adults on glucagon-like peptide-1 (GLP-1) medications. In this Phase 4 cohort, participants reported statistically significant i... - Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026 PRNewsWire, Nov 3, 1:00 PM UTC
– Nine abstracts will be presented, including new data from Phase 4 research examining aesthetic treatment following medical weight loss, with a focus on patient satisfaction and psychosocial outcomes – A digital imag... - AbbVie Reports Third-Quarter 2026 Financial Results PRNewsWire, Oct 30, 11:46 AM UTC
Reports Third-Quarter Diluted EPS of $2.37 on a GAAP Basis, an Increase of Over 100.0 Percent; Adjusted Diluted EPS of $3.82, an Increase of Over 100.0 Percent; These Results Include an Unfavorable Impact of $0.11 Per... - The Countdown Is On: BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Nov. 18 PRNewsWire, Oct 28, 12:00 PM UTC
The holiday celebrates personalized treatment with BOTOX® Cosmetic across four FDA-approved aesthetic indication areas, the one and only of its kind in the United States.1 BOTOX® Cosmetic Day marks the biggest offer o... - Allergan Aesthetics Announces 2026 Grant Recipients of The Confidence Collective, Funded by BOTOX® Cosmetic (onabotulinumtoxinA) PRNewsWire, Oct 27, 12:30 PM UTC
Since its inception, The Confidence Collective has supported more than 500 women entrepreneurs and awarded more than $1.5 million in grants to fuel business growth and empower confidence. In 2026 alone, BOTOX® Cosmeti... - AbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple Myeloma PRNewsWire, Oct 27, 12:00 PM UTC
– Etentamig is a second-generation BCMA-directed bispecific antibody T-cell engager with a clinical profile and dosing schedule that can potentially support treatment across a broad range of settings, including in co... - Allergan Aesthetics Celebrates Eight Years of Engaging Girls in STEM Through Continued Partnership with Girls Inc. PRNewsWire, Oct 26, 12:00 PM UTC
Allergan Aesthetics and Girls Inc. continue their commitment to expanding mentorship, education and career exploration opportunities for girls nationwide. A STEM-focused workshop in San Antonio will bring together 20 ... - U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease PRNewsWire, Oct 23, 7:33 PM UTC
Now with a new route of induction administration, subcutaneous SKYRIZI supports early symptomatic and endoscopic control with an on-body injector (OBI) device throughout the course of treatment In the pivotal Phase 3 ... - AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa PRNewsWire, Oct 22, 1:00 PM UTC
In the Phase 3 INTREPID study, lutikizumab achieved the primary endpoint of Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16 compared with placebo1 Lutikizumab met 8 ranked secondary endpoints, inclu... - Allergan Aesthetics Deepens Science Behind Multimodal Approach at AMWC Dubai, Backed by Growing HArmonyCa™ Evidence PRNewsWire, Oct 21, 12:00 PM UTC
Allergan Aesthetics will present eight scientific posters featuring new and long-term evidence across HArmonyCa™, JUVÉDERM ® , SKINVIVE™ and BOTOX ® Cosmetic The latest HArmonyCa™ data reinforces its dual-action techn... - AbbVie Named Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team, Launches AbbVie Race to Innovate to Support Immunology Community PRNewsWire, Oct 20, 11:55 AM UTC
Multi-year, purpose-driven campaign connects McLaren's on-track performance with support for global patient advocacy organizations serving people living with immune-mediated diseases Through the partnership, AbbVie wi... - AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease PRNewsWire, Oct 19, 8:00 AM UTC
In a Phase 2a study, ABBV-466 achieved higher endoscopic remission rates in patients with Crohn's disease than either anti-IL-23 p19 or anti-α4β7 monotherapy at Week 12, the primary endpoint. The treatment difference ...
Headlines link to their publishers. Research data, not investment advice.